REGISTER
Xuanzhu Pyroxiclib Moves Into First-Line Breast Cancer
Xuanzhu Biopharmaceutical’s CDK2/4/6 inhibitor pyroxiclib has been approved in China for a new indication as first-line endocrine-based treatment for HR-positive, HER2-negative advanced breast cancer, supported by promising results from the Phase III BRIGHT-3 study.

On March 3, the NMPA website showed that a new indication for Xuanzhu Biopharmaceutical’s CDK2/4/6 inhibitor pyroxiclib had been approved in China. It is to be used in combination with an aromatase inhibitor as first-line endocrine initial treatment for patients with HR-positive, HER2-negative advanced breast cancer, as well as for subsequent treatment in patients whose disease progressed after adjuvant therapy with tamoxifen or toremifene.

Pyroxiclib is an oral small-molecule CDK2/4/6 inhibitor independently developed by Xuanzhu Biopharmaceutical, a subsidiary of Sihuan Pharmaceutical. Based on innovative technical design, pyroxiclib shows good enzymatic inhibitory activity against CDK4 and CDK6 and also has favorable inhibitory effects on CDK2 and CDK9.

In May 2025, the drug first received NMPA approval for the treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer:

In combination with fulvestrant for patients whose disease progressed after prior endocrine therapy;

As monotherapy for patients whose disease progressed after having received at least two endocrine therapies and one chemotherapy regimen in the metastatic setting.

At the ESMO Congress 2025, Xuanzhu Biopharmaceutical announced the prespecified interim analysis results from the Phase III BRIGHT-3 study of pyroxiclib in first-line treatment of HR-positive, HER2-negative advanced breast cancer, registration number NCT05257395. The data showed the following:

As of January 10, 2025, at a median follow-up of 20.7 months, median progression-free survival assessed by both investigators and the independent review committee had not yet been reached in the pyroxiclib group, compared with 18.43 months and 19.55 months, respectively, in the control group.

The risk of disease progression was significantly reduced. Compared with placebo plus endocrine therapy, the pyroxiclib regimen reduced the risk of disease progression or death by 47%.

The objective response rate improved markedly. In the intention-to-treat population, the objective response rate reached 63.5% in the pyroxiclib group, significantly better than 42.5% in the control group.

All prespecified subgroups benefited. Consistent progression-free survival benefit was seen across all prespecified subgroups, and in patients with liver metastases, who generally have poorer prognosis, disease risk was reduced by 64%, highlighting notable potential in difficult-to-treat populations.

Safety analysis showed that common adverse events with the pyroxiclib combination regimen, such as diarrhea and neutropenia, were mostly Grade 1 or 2 and could be effectively managed with supportive care or dose adjustment, resulting in an overall controllable safety profile. The convenience of oral administration may also improve patient adherence and quality of life and better fits the concept of chronic disease management in advanced breast cancer.

Breast cancer has become the second most common cancer type, and CDK4/6 inhibitors, as an important treatment option in HR-positive, HER2-negative populations with endocrine resistance, have also been highly sought after, giving rise to multiple blockbusters. According to statistics, the global CDK4/6 inhibitor market reached nearly USD 13.0 billion in 2024, up 18% year over year.

0
0
Loading